VMAT2 and Parkinson’s disease: harnessing the dopamine vesicle

Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum

(2014) C. Pifl et al.   JOURNAL OF NEUROSCIENCE

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

(2014) Kelly M. Lohr et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease

(2013) David S. Goldstein et al.   JOURNAL OF NEUROCHEMISTRY

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease

(2013) Laura Brighina et al.   NEUROBIOLOGY OF AGING

Brain Dopamine–Serotonin Vesicular Transport Disease and Its Treatment

(2013) Jennifer J. Rilstone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons

(2009) Thomas S. Guillot et al.   MOLECULAR NEUROBIOLOGY